About Alzamend Neuro, Inc.
https://www.alzamend.comAlzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
CEO
Stephan Jackman
Compensation Summary
(Year 2024)
Salary $350,000
Bonus $75,000
All Other Compensation $18,617
Total Compensation $443,617
Industry Biotechnology
Sector Healthcare
Went public June 15, 2021
Method of going public IPO
Full time employees 4
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-05-12 | Reverse | 1:9 |
| 2024-07-16 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 3
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $7.35 M
52w High $11.03
52w Low $1.69
P/E -0.85
Volume 41.47K
Outstanding Shares 3.14M
About Alzamend Neuro, Inc.
https://www.alzamend.comAlzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $0 | $998.11K ▼ | $-1M ▲ | 0% | $-0.3 ▲ | $-998.11K ▲ |
| Q1-2026 | $0 | $2.7M ▲ | $-2.7M ▼ | 0% | $-1.28 ▲ | $-2.7M ▼ |
| Q4-2025 | $0 | $1.13M ▲ | $-1.14M ▼ | 0% | $-2.22 ▼ | $-1.13M ▼ |
| Q3-2025 | $0 | $1.04M ▼ | $-1.04M ▲ | 0% | $-0.19 ▲ | $-1.02M ▲ |
| Q2-2025 | $0 | $1.36M | $-1.36M | 0% | $-0.4 | $-1.34M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $4.45M ▼ | $5.09M ▼ | $717.49K ▼ | $4.37M ▼ |
| Q1-2026 | $5.62M ▲ | $6.33M ▲ | $983.31K ▲ | $5.34M ▲ |
| Q3-2025 | $3.36M ▼ | $4.18M ▼ | $725.85K ▼ | $3.45M ▼ |
| Q2-2025 | $4.09M ▲ | $5.01M ▲ | $1.25M ▼ | $3.75M ▲ |
| Q1-2025 | $1.19M | $1.67M | $2.88M | $-1.21M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $-1M ▲ | $-1.17M ▲ | $0 | $0 ▼ | $-1.17M ▼ | $-1.17M ▲ |
| Q1-2026 | $-2.7M ▼ | $-2.36M ▼ | $0 ▲ | $4.04M ▲ | $1.67M ▲ | $-2.36M ▼ |
| Q4-2025 | $-1.14M ▼ | $-688.71K ▲ | $-210K ▼ | $1.49M ▲ | $590.52K ▲ | $-898.71K ▲ |
| Q3-2025 | $-985.78K ▲ | $-1.42M ▲ | $0 | $688.7K ▼ | $-734.94K ▼ | $-1.42M ▲ |
| Q2-2025 | $-1.42M | $-3.4M | $0 | $6.3M | $2.9M | $-3.31M |
CEO
Stephan Jackman
Compensation Summary
(Year 2024)
Salary $350,000
Bonus $75,000
All Other Compensation $18,617
Total Compensation $443,617
Industry Biotechnology
Sector Healthcare
Went public June 15, 2021
Method of going public IPO
Full time employees 4
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-05-12 | Reverse | 1:9 |
| 2024-07-16 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 3
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0